John Neis Biography and Net Worth

Director of Cellectar Biosciences

Mr. Neis has served as a Director of Cellectar since February 2008. Mr. Neis has been Managing Director of Venture Investors LLC since 1986 and heads the firm’s Healthcare practice. He has more than 23 years’ experience in the venture capital industry and has served on the Board of Directors of numerous companies from formation through initial public offering or sale. Mr. Neis currently serves on the Boards of Directors of Virent, Inc., Deltanoid Pharmaceuticals, Inc., and Inviragen, Inc. He is a former member of the Boards of Directors of several firms including TomoTherapy, Third Wave Technologies (acquired by Hologic) and NimbleGen Systems (acquired by Roche). Mr. Neis was appointed to the Board of the Wisconsin Technology Council and the Wisconsin Growth Capital Coalition. He also serves on the advisory boards for the Business School, the Weinert Applied Ventures Program and Tandem Press at the University of Wisconsin – Madison. Mr. Neis holds a Bachelor of Science degree in Finance from the University of Utah, and a Master of Science degree in Marketing and Finance from the University of Wisconsin - Madison. He is a Chartered Financial Analyst.

What is John Neis' net worth?: The estimated net worth of John Neis is at least $18.21 as of December 12th, 2025. Mr. Neis owns 10 shares of Cellectar Biosciences stock worth more than $18 as of October 2nd. This net worth estimate does not reflect any other investments that Mr. Neis may own. Learn More about John Neis' net worth.
How do I contact John Neis?: The corporate mailing address for Mr. Neis and other Cellectar Biosciences executives is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. Cellectar Biosciences can also be reached via phone at (608) 441-8120 and via email at [email protected]. Learn More on John Neis' contact information.
Has John Neis been buying or selling shares of Cellectar Biosciences?: John Neis has not been actively trading shares of Cellectar Biosciences within the last three months. Most recently, John Neis sold 198 shares of the business's stock in a transaction on Friday, December 12th. The shares were sold at an average price of $3.70, for a transaction totalling $732.60. Following the completion of the sale, the director now directly owns 10 shares of the company's stock, valued at $37. Learn More on John Neis' trading history.
Who are Cellectar Biosciences' active insiders?: Cellectar Biosciences' insider roster includes Chad Kolean (CFO), Jarrod Longcor (COO), and John Neis (Director). Learn More on Cellectar Biosciences' active insiders.
Are insiders buying or selling shares of Cellectar Biosciences?: In the last twelve months, Cellectar Biosciences insiders bought shares 2 times. They purchased a total of 17,360 shares worth more than $49,996.80. In the last twelve months, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 198 shares worth more than $732.60. The most recent insider tranaction occured on May, 7th when COO Jarrod Longcor bought 8,680 shares worth more than $24,998.40. Insiders at Cellectar Biosciences own 2.6% of the company. Learn More about insider trades at Cellectar Biosciences.
Information on this page was last updated on 5/7/2026.

John Neis Insider Trading History at Cellectar Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/12/2025	Sell	198	$3.70	$732.60	10
11/14/2017	Sell	173	$44.70	$7,733.10
11/29/2016	Buy	11,111	$44.70	$496,661.70
8/20/2014	Buy	8,957	$112.50	$1,007,662.50

John Neis Buying and Selling Activity at Cellectar Biosciences

Cellectar Biosciences Company Overview

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Today's Range

Now: $1.80

$1.79

$1.98

50 Day Range

MA: $2.40

$1.80

$2.66

2 Week Range

Now: $1.80

$1.79

$6.52

Volume

43,074 shs

Average Volume

387,800 shs

Market Capitalization

$16.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58